NCT03922321View on ClinicalTrials.gov

Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 22, 2019

Primary Completion Date

February 29, 2020

Study Completion Date

May 21, 2020

Conditions
Graves' Ophthalmopathy
Interventions
DRUG

RVT-1401

RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.

Trial Locations (4)

V5Z 3N9

UBC/VGH Eye Care Center, Vancouver

M3C 0G9

Toronto Retina Institute, North York

K1H 8L6

University of Ottwa Eye Institute, Ottawa

H1T 2M4

CIUSSS de I'Est-de-I'lle-de-Montreal, Installation Maisonneuve- Rosemont, Montreal

Sponsors
All Listed Sponsors
lead

Immunovant Sciences GmbH

INDUSTRY

NCT03922321 - Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO) | Biotech Hunter | Biotech Hunter